BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
2.900
-0.090 (-3.01%)
At close: Sep 17, 2025, 4:00 PM EDT
2.911
+0.010 (0.36%)
After-hours: Sep 17, 2025, 7:59 PM EDT
BioXcel Therapeutics Revenue
BioXcel Therapeutics had revenue of $120.00K in the quarter ending June 30, 2025, a decrease of -89.13%. This brings the company's revenue in the last twelve months to $868.00K, down -63.88% year-over-year. In the year 2024, BioXcel Therapeutics had annual revenue of $2.27M with 64.20% growth.
Revenue (ttm)
$868.00K
Revenue Growth
-63.88%
P/S Ratio
15.36
Revenue / Employee
$23,459
Employees
37
Market Cap
56.98M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.27M | 886.00K | 64.20% |
Dec 31, 2023 | 1.38M | 1.01M | 268.00% |
Dec 31, 2022 | 375.00K | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
BTAI News
- 7 days ago - BioXcel Therapeutics, Inc. (BTAI) Discuses On SERENITY At-Home Pivotal Phase 3 Safety Trial Results Call (Transcript) - Seeking Alpha
- 7 days ago - BioXcel Drug Calms Agitation At Home For Schizophrenia, Bipolar Patients - Benzinga
- 7 days ago - BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewsWire
- 13 days ago - BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 21 days ago - BioXcel Seeks FDA Label Expansion For Schizophrenia Treatment - Benzinga
- 21 days ago - UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI® - GlobeNewsWire
- 21 days ago - BioXcel's agitation drug meets main goal in at-home study - Reuters
- 21 days ago - BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI® - GlobeNewsWire